Another COVID-19 vaccine shows promise
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Interim results of a phase 1-2a trial of a COVID-19 candidate vaccine, Ad26.COV2.S, suggest it can provoke a neutralising antibody response in 90 per cent of recipients 29 days after administration, reaching 100 per cent after 57 days. And white blood cell responses were boosted in 76 - 83 per cent of recipients 14 days after administration. These trials were focused on the vaccine candidate's safety and ability to produce immune responses, and the results suggest it should be developed further, the authors say.
Journal/conference: NEJM
Link to research (DOI): 10.1056/NEJMoa2034201
Organisation/s: Janssen Vaccines and Prevention, the Netherlands
Funder: Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276.
Attachments:
Note: Not all attachments are visible to the general public
